Infectious Diseases clinical trials

Explore recruiting infectious diseases clinical trials.

Recruiting infectious diseases studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Infectious Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarithromycin tablets 500 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Clarithromycin 500 mg coated tablets Manufactured by: Sanofi Medley Pharmaceuticals Ltd. Brazilian Industry, in healthy adult, human subjects under fasting condition.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

European Clinical Research Alliance on Infectious Diseases – primary care adaptive platform trial for pandemics and epidemics (ECRAID-Prime)

Germany, France, Belgium, Poland, Ireland, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of early dexamethasone on major complications and all-cause mortality in severe burns

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis directed at the host.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Infectious Diseases trials by city

Infectious Diseases in Toronto Infectious Diseases in Vancouver Infectious Diseases in Montreal Infectious Diseases in Calgary Infectious Diseases in Edmonton Infectious Diseases in Ottawa Infectious Diseases in Winnipeg Infectious Diseases in Quebec City Infectious Diseases in Hamilton Infectious Diseases in Kitchener Infectious Diseases in London Infectious Diseases in Halifax Infectious Diseases in New York Infectious Diseases in Los Angeles Infectious Diseases in Chicago Infectious Diseases in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease